The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.
  • The agreement for the distribution of Sentia runs for three years and can be renewed and terminated by either company
  • Sentia analyses sulphur dioxide in post-fermentation white and red wine in a quick and accurate manner
  • Sulphur dioxide is typically added to wines to protect them from oxidisation and spoilage
  • UBI has ended the day 2.74 per cent in the green with shares trading at 75 cents

Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.

The distribution period for the Sentia device runs for three years and can be renewed and terminated by either company.

“We are delighted to partner with Sentia in the United States. We have received positive feedback from our customers and believe Sentia will make a significant impact in the wine testing market in the USA,” Wine & Beer Supply CEO Dave Robertson said.

It’s been a busy couple of days for UBI, entering an agreement with Singularity SpA for the distribution of Sentia in Chile just yesterday.

Sentia analyses sulphur dioxide in post-fermentation white and red wine. Sulphur dioxide is typically added to wines to protect them from oxidisation and spoilage.

Results are then received in under a minute instead of the several days it takes a lab.

“Securing another distributor in the U.S. is a positive step in the commercialisation of Sentia globally,” UBI CEO John Sharman commented.

“Wine & Beer Supply has a strong presence in the U.S., particularly in the eastern half of the U.S. and will give Sentia greater access to the 11,500 wineries across the country,” he added.

UBI has ended the day 2.74 per cent in the green with shares trading at 75 cents in a $129.6 million market cap.

UBI by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system